Evidence map›Paper›PMID 41303006›Full record

ArticleJournal of clinical medicine2025

Comprehensive Evaluation of Elexacaftor/Tezacaftor/Ivacaftor in Paediatric Cystic Fibrosis: Nutritional, Pulmonary, and Quality-of-Life Outcomes.

Katarzyna Walicka-Serzysko, Magdalena Postek, Monika Mielus, Urszula Borawska-Kowalczyk, Justyna Milczewska, Katarzyna Zybert, Łukasz Wozniacki, Anna Wołkowicz, Dorota Sands

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

Patient-Reported Health-Related Quality of Life in Romanian Patients with Cystic Fibrosis in the Era of Highly Effective CFTR Modulator Therapy: A National Cross-Sectional Mixed-Methods Survey.Journal of clinical medicine · 2026
Article
The New Landscape of Cystic Fibrosis in the Era of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy.Journal of mother and child · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katarzyna Walicka-SerzyskoCystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland.ORCID 0000-0002-6496-8737

Magdalena PostekCystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland.ORCID 0000-0002-1678-3316

Monika MielusCystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland.ORCID 0000-0003-1229-1848

Urszula Borawska-KowalczykCystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland.

Justyna MilczewskaCystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland.ORCID 0000-0003-3365-9963

Katarzyna ZybertCystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland.

Łukasz WozniackiCystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland.ORCID 0000-0002-8702-3808

Anna WołkowiczCystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland.ORCID 0000-0001-9500-9814

Dorota SandsCystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland.ORCID 0000-0002-4601-5158

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

body compositionCFTR modulatorcystic fibrosisfat free massfat masshealth-related quality of lifelung clearance indexnutritional statusspirometry

Identifiers

PMID41303006

DOI10.3390/jcm14227969

PMCPMC12653656

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.